Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation

Biochemical and Biophysical Research Communications

Volumn 440, Issue 1, 2013, Pages 76-81

  Kim, Kook Hwan ^a   Jeong, Yeon Taek ^a   Kim, Seong Hun ^a   Jung, Hye Seung ^b   Park, Kyong Soo ^b   Lee, Hae Youn ^a   Lee, Myung Shik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

AMPK; ATF4; Diabetes; FGF21; Metformin

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; FIBROBLAST GROWTH FACTOR 21; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CLINICAL ARTICLE; DIABETES MELLITUS; FIBROBLAST; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; RESPIRATORY CHAIN; TREATMENT DURATION;

AMPK; ATF4; DIABETES; FGF21; METFORMIN;

ACTIVATING TRANSCRIPTION FACTOR 4; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; EIF-2 KINASE; ELECTRON TRANSPORT; EUKARYOTIC INITIATION FACTOR-2; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; MITOCHONDRIA; RATS; UP-REGULATION;

EUKARYOTA; MAMMALIA; MUS; RATTUS;

EID: 84885383560     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.026     Document Type: Article

References (23)

1. Adams A.C., Kharitonenkov A. FGF21: the center of a transcriptional nexus in metabolic regulation. Curr. Diabetes Rev. 2012, 8:285-293.
2. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
3. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J.K., Gerard R.D., Burgess S.C., Hammer R.E., Mangelsdorf D.J., Kliewer S.A. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
4. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
5. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S., Hecht R., Li Y.S., Lindberg R.A., Chen J.L., Jung D.Y., Zhang Z., Ko H.J., Kim J.K., Veniant M.M. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
6. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
7. Klip A., Leiter L.A. Cellular mechanism of action of metformin. Diabetes Care 1990, 13:696-704.
8. Shin N.R., Lee J.C., Lee H.Y., Kim M.S., Whon T.W., Lee M.S., Bae J.W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2013, in press.
9. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.
10. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., Zhou G., Williamson J.M., Ljunqvist O., Efendic S., Moller D.E., Thorell A., Goodyear L.J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002, 51:2074-2081.
11. Hardie D.G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 2007, 47:185-210.
12. Foretz M., Hebrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., Sakamoto K., Andreelli F., Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
13. Kalender A., Selvaraj A., Kim S.Y., Gulati P., Brule S., Viollet B., Kemp B.E., Bardeesy N., Dennis P., Schlager J.J., Marette A., Kozma S.C., Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010, 11:390-401.
14. Muise E.S., Azzolina B., Kuo D.W., El-Sherbeini M., Tan Y., Yuan X., Mu J., Thompson J.R., Berger J.P., Wong K.K. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol. Pharmacol. 2008, 74:403-412.
15. Kim K.H., Jeong Y.T., Oh H., Kim S.H., Cho J.M., Kim Y.N., Kim S.S., Kim do H., Hur K.Y., Kim H.K., Ko T., Han J., Kim H.L., Kim J., Back S.H., Komatsu M., Chen H., Chan D.C., Konishi M., Itoh N., Choi C.S., Lee M.S. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 2013, 19:83-92.
16. Laderoute K.R., Amin K., Calaoagan J.M., Knapp M., Le T., Orduna J., Foretz M., Viollet B. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell Biol. 2006, 26:5336-5347.
17. Maida A., Lamont B.J., Cao X., Drucker D.J. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011, 54:339-349.
18. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348(Pt. 3):607-614.
19. Liu L., Wise D.R., Diehl J.A., Simon M.C. Hypoxic reactive oxygen species regulate the integrated stress response and cell survival. J. Biol. Chem. 2008, 283:31153-31162.
20. Rath E., Berger E., Messlik A., Nunes T., Liu B., Kim S.C., Hoogenraad N., Sans M., Sartor R.B., Haller D. Induction of dsRNA-activated protein kinase links mitochondrial unfolded protein response to the pathogenesis of intestinal inflammation. Gut 2012, 61:1269-1278.
21. Baker B.M., Nargund A.M., Sun T., Haynes C.M. Protective coupling of mitochondrial function and protein synthesis via the eIF2alpha kinase GCN-2. PLoS Genet. 2012, 8:e1002760.
22. Miller R.A., Chu Q., Xie J., Foretz M., Viollet B., Birnbaum M.J. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013, 494:256-260.
23. Nygaard E.B., Vienberg S.G., Orskov C., Hansen H.S., Andersen B. Metformin stimulates FGF21 expression in primary hepatocytes. Exp. Diabetes Res. 2012, 2012:465282.